Gator Bio Wins Key U.S. Patent Rulings in Its Dispute with Sartorius

Gator Bio prevailed at the ITC after a full hearing and later secured dismissal of infringement claims in federal court.

Sartorius began its U.S. International Trade Commission case by asserting claims from four U.S. patents against Gator Bio’s BLI products. Before the hearing, Sartorius itself withdrew three of those patents and all but one claim of the fourth. Gator Bio won on that remaining claim. The Administrative Law Judge found no infringement, and the Commission affirmed the no-infringement result and terminated the investigation with a final finding of “no violation.” Sartorius did not appeal.

In February 2026, the U.S. District Court for the Northern District of California dismissed additional Sartorius infringement claims, including its claim of willful infringement, and described part of Sartorius’s position as “self-contradictory.” The remaining federal case is narrow and currently on hold.

What this means for you. Nothing in these U.S. rulings prevents customers from continuing to buy or use Gator Bio products. The district court has said Sartorius is “unlikely to obtain injunctive relief,” meaning unlikely to obtain an order that could stop or restrict future sales of Gator Bio products, and three of the four patents in the federal case have now expired. These proceedings concern U.S. patent rights only and do not determine patent rights in Europe, Asia, or elsewhere. Laboratories worldwide continue to run Gator Bio systems with confidence.